Faeth Therapeutics 3Q 2026: Net loss $20.4M, diluted loss per share $0.79— 10-Q Summary

What happened

Faeth Therapeutics reported a net loss of $20.4 million for the third quarter of 2026, compared with a $4.6 million loss a year earlier. Basic and diluted loss per share narrowed to $0.79 from $3.62.

Confirmed

Global impact / market context

The wider loss shows the company is spending more as it runs mid-stage cancer trials, which consume cash before any product revenue arrives. The narrower per-share loss suggests more shares are outstanding, so each share absorbs a smaller slice of the loss.

Analyst inference

Faeth is a clinical-stage oncology company with no approved product revenue in the article. Investors weigh trial spending against expected data readouts, including Phase 2 endometrial results due by year-end 2026 and breast cancer interim data expected in 2027.

Analyst inference

What to watch

1. Topline data from the ongoing Phase 2 endometrial cancer study of PIKTOR are anticipated by year-end 2026, a key readout that could reshape the company's pipeline value. Confirmed
2. The company should disclose how far its remaining cash stretches against trial costs, since a widening loss raises the chance it will need to raise more money. Proposed
3. Watch whether the Phase 1/2 solnerstotug trial completion and 2027 breast cancer interim data keep research spending high, which would deepen losses before any revenue. Analyst inference

Evidence

• Original source link unavailable